DXS NewsDXS Newshttp://216.122.5.231/Content/News.aspx?Z=7DXSDXSDXSCooltide Interactive RSS Feederhttp://www.dxsgenotyping.com//RequestFile/dxs_news.jpg&Type=F&Page=1&ID=bb2ff093-3456-412a-abfe-2048f685f5eaDXS Newshttp://216.122.5.231/Content/News.aspx?Z=7Genzyme Announces Sublicense Agreement with DxShttp://216.122.5.231/Content/News.aspx?Z=7Pursues Global Expansion of Lung Cancer Testing PortfolioNew Year accolade for DxShttp://216.122.5.231/Content/News.aspx?Z=7DxS one of the northwest?s internationally-recognised biotechnology firms has a lot to celebrate in 2008. Based at the University of Manchester Incubator Company facilities DxS has not only grown its staff by 28% inside a year and expanded its laboratory facilities, the company received a prestigious award at the recent BioNow 2007 awards evening.DxS and Epigenomics AG enter Into Strategic Cross-Licensing Agreement for the Use of Scorpions? Technology in DNA Methylation based Testinghttp://216.122.5.231/Content/News.aspx?Z=7The K-RAS Mutation Test Kit has now been CE-Marked and will be available for professional diagnostic use from 1st January 2008.http://216.122.5.231/Content/News.aspx?Z=7DxS K-RAS Mutation Detection Kit Used To Assess Tumour Mutation Status Prior to Treatment with Amgen?s Vectibix?http://216.122.5.231/Content/News.aspx?Z=7DxS expand their portfolio of cancer mutation products, with the launch of a B-RAF Mutation Detection Kithttp://216.122.5.231/Content/News.aspx?Z=7DxS signs a license with Canadian company for its class leading Scorpions? technologyhttp://216.122.5.231/Content/News.aspx?Z=7EGFR detection in lung cancer study confirms superior performance of DXS EGFR Kithttp://216.122.5.231/Content/News.aspx?Z=7Tokyo Cancer Institute Hospital lung cancer study data is published in ChestSignificant step towards the delivery of diagnostics for cancer drug responsehttp://216.122.5.231/Content/News.aspx?Z=7UC Davis Cancer Center presents enhanced EGFR detection data from plasma, through collaboration with DxSK-RAS Mutation Detection Kit Launched by DxS ? the industry leaders in tumour mutation analysishttp://216.122.5.231/Content/News.aspx?Z=7DxS launch TheraScreen? ? The first CE marked diagnostic for EGFR detectionhttp://216.122.5.231/Content/News.aspx?Z=7